When Samir Ounzian left London a decade ago to study a little-understood branch of the genome at a Swiss lab, he wasn’t sure what he would find. Known as long-non-coding RNA, these sections were translated into looping rings of RNA — hence the name — but didn’t actually translate into proteins, and no one was …
A new RNA startup looks to reimagine heart treatments, with eyes set on Entresto Read More »
HAYA Therapeutics, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), closed its CHF 18 million Seed round. The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq, and Viva BioInnovator. HAYA Therapeutics was a Venture Kick winner and a Venture …
Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic. New York-based RenBio announced a $24 million series A round, led by Ruentex Group, to move its lead bispecific antibody into phase 1/2 trials by the end of the year. …